報價延遲最少15分鐘:2024/04/27 15:17 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.26 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.66/--
|
|
企業價值
7.24M
|
| 資產負債 |
|
每股賬面淨值
0.22
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/04/27 15:17 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. Itfocuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity. |